Welcome to the 7th edition of the Global Top 200 cannabis lawyers 2026-2027 published by Cannabis Law Report & Cannabis Law Journal.
We have compiled the lawyers and law firms we believe to be the top 200 cannabis practitioners and practices around the world via our annual survey of clients and lawyers in the cannabis legal services sector, this research is combined with our personal editorial decisions based on our daily reporting for the past decade. Read More
Thank you, Sean Hocking – Editor: The Global Top 200 Cannabis Lawyers
In the directory we do not rank lawyers within the top 200 instead we aim to do our utmost to balance client recommendations and editorial decisions with as wide a geographical spread as possible to allow prospective clients to source cannabis, hemp & CBD legal specialists in the jurisdictions they wish to do their business.
When we started publishing the top 200 no other publisher showed any interested in highlighting cannabis lawyers….
- Who they were?
- What they did ?
- Where they did it?
UK publishers Chambers & Legal 500 have both been slowly building their database of cannabis lawyers which gets a little larger each year.
I would note that, in the main, both publications have not looked outside existing major North American firms and those larger European firms who have built cannabis practices using practitioners who work in their primary practice and then cannabis work is secondary work as part of a team on specific projects.
These publications do err on the side of the top end of town and now with US re-scheduling on the way the information about the firms they highlight are of use for those companies that are thinking of national or multi-state operations .
Here at the Top 200 we still see that the vast majority of cannabis specific lawyers serve SME businesses who need people rather than teams to work with.
You will also find dotted around the place organisations like the ABA and state bars who provide limited lists of individuals and firms. The misnomered INCBA is also a good source for researching cannabis and hemp lawyers in the USA working actively in the space.
The 2026-2027 Top 200 Cannabis lawyers 7th edition now joins our small family of publications that also includes the Top 200 Psychedelic Lawyers, the Top 200 Cannabis Accountants and the Top 200 Cannabis Consultants.
Next to publish will be our Top 200 Global Cannabis Policy Experts Guide.
Cannabis practices can broadly be subdivided into 3 categories
Respected solo or under 5 partner firms with solid local state experience, history and clients
Early adopter firms who specialise in cannabis offering full service client support with an emphasis on state based compliance services
Existing full service law firms who have drawn individuals with specific skill-sets from their existing practice to build national full service cannabis practices.
Regional Analysis
North America
As with all prior editions, the majority of the legal cannabis professionals listed in the directory are based in North America although every year we move forward we are seeing more lawyers taking up the mantle outside the US.
Prior to this edition lawyers were located in a number of specific cities as you can see in the list below but it is also worth noting that this is the first year that it is safe to say that where ever you are in the US you won’t be far from a lawyer with some knowledge of cannabis licensing, compliance or litigation.
We would highlight, as we have for the last few years, Denver, New York Los Angeles & San Francisco as the premier centers of excellence with Washington DC, Portland (OR) , Seattle, Boston, Chicago, Miami & Las Vegas following close behind.
2026 has brought unprecedented regulatory volatility to the United States cannabis and hemp markets, creating an intricate web of compliance obligations, structural corporate overhauls, and litigation risks.
For corporate lawyers and specialized law firms, this transitional period moving into 2027 represents a profound shift away from the traditional state-by-state advisory model toward a highly complex federal practice driven by administrative law, strict structural re-engineering, and constitutional challenges.
The most transformative development for cannabis practitioners is the Department of Justice’s April 2026 final order reclassifying FDA-approved marijuana drug products and state-licensed medical marijuana as Schedule III controlled substances.
By separating medical operations from the strict prohibitions of Schedule I, the federal government has created a starkly bifurcated marketplace.
For legal counsel, the immediate windfall lies in corporate tax strategy. Reclassification has effectively untethered state-licensed medical operators from the punitive grasp of Internal Revenue Code Section 280E, allowing long-denied business deductions, or not?
Law firms are now restructuring client entities to isolate medical components from adult-use recreational business segments, which remain classified under Schedule I. However, this dual-framework creates significant compliance friction, particularly regarding employment law, corporate disclosure, and ongoing appellate litigation in the D.C. Circuit questioning the validity of the administrative shift.
Simultaneously, the hemp-derived cannabinoid market is facing an existential regulatory reckoning that will dominate legal practices through 2027. Tucked into the 2026 Extensions Act, Section 781 closed the structural “loophole” created by the 2018 Farm Bill. Moving the enforcement baseline from a 0.3% delta-9 THC limit to a 0.3% total THC cap, which now encompasses THCA, effectively dismantling the raw flower market.
Furthermore, a strict federal retail product cap of 0.4 milligrams of total THC per container is scheduled to take full effect on December 11, 2026. Because a standard retail gummy or beverage can easily exceed this limit, 95% of existing intoxicating hemp products will be functionally criminalized as Schedule I controlled substances overnight.
For transactional and compliance attorneys, this statutory cliff requires rapid triage. Law firms are busy auditing inventory valuations, rewriting supply chain distribution agreements, and conducting extensive risk assessments for common carriers, financial tech providers, and payment processors who are scaling back exposure ahead of the December deadline.
As the industry pivots into 2027, the role of legal counsel has evolved from helping businesses circumvent federal barriers to actively defending them within heavily policed boundaries. Law firms must prepare clients for a wave of state and federal enforcement actions, product re-formulation mandates, and commercial litigation stemming from broken supply chains.
The “normalization” of the industry is finally arriving, but it is doing so through heavy administrative oversight, demanding that attorneys possess deep expertise in FDA regulations, administrative procedure, and sophisticated corporate structuring.
Europe
The European regulated cannabis and hemp market in 2026 is moving toward a highly litigious inflection point. For law firms and corporate lawyers specializing in life sciences, regulatory affairs, and international trade, the landscape is shifting from pure transactional advisory to complex compliance and regulatory litigation.
The market is projected to exceed €2 billion by 2027. However, the core legal reality is that Europe has no single, harmonized market. Instead, operators must navigate a fragmented tapestry of 30-plus distinct national legal regimes. It’ll be a while before Brussels can agree on anything covering the entire European Union legal framework.
Germany remains the undisputed economic center of gravity for European medical cannabis. By reclassifying medical cannabis under the German Medicines Act (AMG) in 2024, the nation triggered a massive import and patient surge that continues to dominate the market through 2026. However, heading into 2027, lawyers face a stricter regulatory backlash, both in Berlin and across provincial governments and courts.
Law firms must now think about advising international suppliers on tightening health controls. Crucially, upcoming reforms like Germany’s GKV-Beitragsstabilisierungsgesetz have restricted statutory health insurance reimbursement for raw flower, forcing operators to redesign business models around private payers and hybrid telemedicine clinics.
Meanwhile, France is preparing to transition its long-running pilot into a permanent medical framework by 2027, beware French bureaucracy, though!
The planned framework strictly integrates cannabis into the traditional pharmaceutical system, completely excluding raw flower in favor of oils and vaporized formats. Attorneys advising international cultivators must ensure strict compliance with EU-GMP (Good Manufacturing Practice) standards, as compliance technology and cross-border pharmaceutical licensing are primary drivers of active legal work.
The Industrial Hemp and CBD Battleground In Europe
For corporate lawyers, the industrial hemp and CBD sector currently represents an administrative minefield. While the landmark Kanavape ruling established that CBD is not a narcotic, member states continuously invoke Article 36 of the TFEU (the public health derogation) to restrict cross-border trade.
| Regulatory Layer | 2026 Status | 2027 Outlook | Legal Focus Area |
| Ingestible CBD / Novel Foods | Unharmonized gray market; EFSA stalls over missing safety data. | EFSA’s restrictive ~2 mg/day safe intake level guidelines reshape enforcement. | Risk mitigation strategies for legacy dosages; auditing packaging claims. |
| Hemp Flower & Leaves | Crackdowns in France, Italy, and Greece banning retail raw flower. | Final ruling from Italy’s Council of State at the CJEU. | Cross-border litigation using free movement of goods arguments. |
| THC Contaminant Caps | Implementation of Regulation (EU) 2026/1828 capping infusion limits. | Universal mandatory labeling warnings enforced. | Mandated compliance audits for food operators and product formulations. |
Furthermore, the European Industrial Hemp Association (EIHA) is actively lobbying to lift field cultivation THC ceilings to 1.0%. However, the European Commission’s planned inclusion of hemp blossoms under the Common Agricultural Policy (CAP) by 2027 will require lawyers to draft entirely new supply chain contracts and structure compliance parameters from scratch.
The Elephant In The Room: Adult-Use Pilot Frameworks
The commercial commercialization of adult-use cannabis remains highly restricted. Legal frameworks in Germany (Pillar 1), Malta, Luxembourg, and the Czech Republic are centered strictly around non-profit social clubs, decriminalization, and home cultivation.
True commercial retail opportunities are currently confined to localized, data-tracking pilot programs, such as Switzerland’s trial systems and the Netherlands’ seed-to-sale supply experiment.
For law firms, the legal workload moving into 2027 will focus on M&A consolidation driven by medical market price compression, and building defensive litigation strategies to challenge national protectionist enforcement against hemp derivatives.
LATAM
The LATAM Regulated Cannabis and Hemp Market: A Legal Perspective on 2026–2027
As the regulated cannabis and hemp markets across Latin America (LATAM) transition from 2026 into 2027, law firms and practitioners are witnessing a structural pivot, even if it is in slow motion.
The era of speculative, hyper-growth projection has been replaced by a rigorous, highly technical compliance landscape. For legal counsel, the primary challenge is no longer navigating a complete absence of rules, but managing a complex “regulatory mosaic” across jurisdictions that demand strict corporate, sanitary, and agricultural alignment.
Brazil’s Compliance Boom
Brazil has consolidated its status as the most lucrative medical jurisdiction in the region. Following landmark legal precedents, Brazil’s health regulatory agency, ANVISA, enacted a overhauled medical cannabis framework (RDC No. 1,015/2026).
For law firms, this has triggered a massive wave of mandatory advisory work. Under the new rules, active ingredients (APIs) and finished products must undergo strict risk assessments. Legal counsel are heavily engaged in advising corporate clients on post-market compliance, such as the mandatory annual preparation of Periodic Benefit-Risk Assessment Reports (PBRER).
Additionally, ANVISA’s separation of a 0.3% THC limit for cultivation and a 0.2% THC limit for sanitary health authorization requires corporate attorneys to structure supply chains meticulously to prevent immediate license cancellations.
Geopolitical and Structural Shifts in Colombia
Colombia remains a vital export powerhouse, serving as a top global supplier of medical cannabis flowers to Europe. However, the recent election of President Espriella has introduced a more conservative political tone regarding full adult-use legalization.
Consequently, lawyers in 2026 are focusing their efforts on the robust medical and scientific framework protected by statutory law. Law firms are actively helping international operators capitalize on Colombia’s new rules allowing dry flower medical dispensaries. Corporate attorneys are structuring joint ventures and local partnerships to successfully navigate the bureaucratic friction of obtaining stable import/export permits under a more skeptical executive branch.
Regional Convergence, IP, and M&A Dynamics
Heading into 2027, several key legal trends are dictating the billable hours of LATAM firms:
Regulatory Reliance: Agencies like ANVISA are increasingly accepting equivalent documentation from member states of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Cross-border legal teams are leveraging this to expedite the internationalization of global technologies into South America.
Intellectual Property Protection: With markets like Peru and Argentina expanding their domestic catalogs of authorized natural products and magistral preparations, securing trademarks and protecting plant variety rights have become high-priority mandates.
Ultimate Beneficial Ownership (UBO) & Transparency: Strict new compliance laws across Central and South America require total transparency regarding beneficial owners. Firms must ensure that foreign investors do not run afoul of anti-money laundering regulations when backing local entities.
Conclusion for Legal Practitioners
Moving into 2027, the role of law firms in LATAM has evolved from lobbying for legalization to enforcing granular operational compliance. Success for international operators relies on local sponsors, verticalized pharmaceutical-grade compliance, and robust traceability systems. Law firms that possess specialized, multi-jurisdictional administrative law expertise are uniquely positioned to capture significant market share in this maturing multi-million dollar sector.
Key Legal Implications for Practice Groups
For regional law firms planning their 2027 strategy, the following practice groups will see the highest demand:
Administrative & Sanitary Law: Defending clients against sudden license cancellations due to the 6-to-12 month adaptation deadlines imposed by regional health authorities.
Corporate & M&A: Structuring local joint ventures, ensuring compliance with Beneficial Ownership Registries, and managing cross-border supply contracts.
Intellectual Property: Navigating patent filings for synthetic cannabinoids and registering trademarks for regional medical brands.
Middle East & Levant
Moving from 2026 into 2027, the regulated cannabis and hemp markets across Turkey and the broader Middle East are undergoing an asymmetric regulatory evolution. Long characterized by strict prohibition, the region is slowly transitioning toward state-sanctioned, highly managed monetization of low-THC and medical cannabinoid products. For law firms and corporate counsel, this shifting landscape creates complex challenges in cross-border compliance, multi-agency licensing, and supply chain tracing.
Turkey’s Rigid Institutionalization
Turkey has established itself as the regulatory blueprint for cannabinoid reform in the region. Following the landmark legislative changes of late 2025, the Turkish government enacted two pivotal decrees on January 31, 2026: the Regulation on Cannabis Cultivation and Control and the Regulation on Products Derived from Cannabis.
This framework officially expanded Turkey’s historic industrial hemp program into the healthcare sector. It established a rigid 0.3% THC threshold to separate product regimes.
The market is divided into four distinct legal categories
Medical products
Health products
Support products
Cosmetic products
For lawyers representing pharmaceutical and agricultural clients, navigating the dual-agency oversight is highly complex. The Ministry of Agriculture and Forestry strictly controls cultivation across designated provinces. Concurrently, the Turkish Medicines and Medical Devices Agency (TMMDA/TITCK) maintains absolute authority over downstream licensing, mandatory electronic track-and-trace systems, and pharmacy-only distribution. E-commerce remains completely prohibited. Corporate counsel must advise international investors that while Turkey is building an export-oriented ecosystem, domestic compliance mirrors strict narcotics and pharmaceutical decree pricing models rather than relaxed European wellness markets.
The Broader Middle East
Outside of Turkey, the Middle East presents a fragmented regulatory environment. Regional markets are bifurcated between progressive medical import regimes and unwavering criminal prohibition.
MIDDLE EAST CANNABINOID REGULATORY MODELS: PHARMACEUTICAL HYBRID – Turkey, Israel, select GCC
Pharmacy-only distribution
THC limitations (<0.3%)
Mandatory electronic tracking
Strictly regulated import paths
TOTAL PROHIBITION – Majority of GCC & Levant
Zero-tolerance policies
High risk of border seizures
Broad definitions of controlled substances
Heavy criminal penalties
Israel remains the regional exception with its highly mature, deeply integrated medical cannabis ecosystem. However, within the Gulf Cooperation Council (GCC), jurisdictions like the United Arab Emirates and Saudi Arabia maintain zero-tolerance policies toward recreational use or over-the-counter CBD wellness goods.
For law firms managing international logistics, shipping, or family office investments, a primary focus entering 2027 is risk mitigation at customs borders. Many Middle Eastern jurisdictions do not differentiate between industrial hemp, CBD isolates, and high-THC cannabis. Bringing unauthorized products across borders carries heavy penalties. Legal advisors must ensure that any corporate medical imports utilize specific, government-to-government named-patient channels or specialized narcotics import permits.
Critical Focus Areas for Law Firms (2026–2027)
1. Supply Chain Traceability & Tech-Compliance
Lawyers must draft ironclad standard operating procedures (SOPs) that align with mandatory state-run electronic tracking infrastructure. Any vulnerability in seed-to-sale reporting can trigger immediate license revocations or severe criminal liability under anti-trafficking statutes.
2. Intellectual Property & Strain Registration
With Turkey using state-developed seed varieties (such as Vezir and Narli), international operators require local counsel to structure joint ventures and technology-transfer agreements. Protecting international proprietary genetics within local state-run agricultural networks will be a key legal battlefield in 2027
3. Strict Compliance Over Wellness Marketing
Because consumer retail and online marketing are banned, law firms must vet all corporate communications. Products containing cannabinoids cannot be marketed using standard lifestyle or wellness campaigns; they must follow the rigorous, science-backed requirements of the healthcare sector.
As the region heads into 2027, the Middle East and Turkey offer viable opportunities for highly capitalized pharmaceutical, agricultural, and biotech entities. Success in these markets requires a strict, defensive legal approach. Legal counsel must prioritize absolute adherence to domestic sovereign oversight, stringent THC thresholds, and tightly controlled pharmacy distribution networks
Africa
As the African cannabis and hemp market heads toward 2027, law firms and corporate counsel face a highly fragmented and dynamic regulatory landscape. Driven by the dual imperatives of economic diversification and access to the African Continental Free Trade Area (AfCFTA), nations are rapidly shifting from absolute prohibition to complex, specialized compliance regimes.
For legal practitioners, advising international investors, local cooperatives, and pharmaceutical entities requires navigating a sharp jurisdictional divide between adult personal use, export-focused medicinal cultivation, and industrial hemp frameworks.
Jurisdictional Profiles & Compliance Realities
The Regional Market Leaders: South Africa & Morocco
South Africa: Operating under the newly enacted Cannabis for Private Purposes Act (CfPPA), South Africa remains the only country on the continent to protect adult-use private possession. Legal attention in late 2026 centers on the finalized Justice Ministry regulations, which clarify strict individual allowances (proposing a 750g limit and 5 plants). However, commercial adult-use sales still remain strictly prohibited (mostly ignored) outside of licensed medicinal (SAHPRA) and industrial hemp permit channels managed by the Department of Agriculture, Land Reform and Rural Development (DALRRD). Corporate attorneys are heavily focused on navigating these multi-agency regulatory boundaries.
Morocco: Sees itself as the continent’s regulatory crown jewel for export operations. Overseen by the national regulator, ANRAC, Morocco’s market has achieved some sense of structural maturity with thousands of active cultivation and processing permits. Moving into 2027, the focus for law firms is cross-border trade compliance. Legal teams are helping local operators manage Moroccan Agency for Medicines and Health Products (AMMPS) registrations for over 100 approved products,including cosmetics and supplements, destined for strict European Union and Australian pharmaceutical networks.
West & East Africa: Industrial and Strict Medical Regimes
Ghana: Following recent legislative shifts, Ghana’s focus remains squarely on industrial hemp (THC under 0.3%). Legal advisors are primarily handling structural joint ventures in textiles and eco-construction materials while establishing robust quality assurance protocols to avoid criminal liability under remaining anti-narcotics legislation.
Uganda & Rwanda: Both nations enforce tightly controlled, state-vetted pathways. Under the Narcotics and Psychotropic Substances Act, Uganda restricts licenses exclusively to specialized medical cultivation and scientific research. Licenses are exceptionally scarce, requiring significant administrative and legal manouvering. Rwanda follows a mirror policy, strictly policing its medical and industrial export framework to protect “public safety” while working on trying to capture high-value EU-GMP global supply chains.
Southern Africa & Central Africa: Emerging Frontiers
Zambia & Botswana: Zambia has progressively mapped out its regulatory infrastructure for medical exports and industrial hemp to lure foreign currency. Law firms are focusing on licensing high-capital cultivation processing plants. Conversely, Botswana remains a highly conservative jurisdiction, presenting severe legal and regulatory hurdles for commercial entrants, with a framework that remains mostly restricted.
Tanzania & Democratic Republic of Congo (DRC): In both nations, cannabis exists in a complex paradigm. While the DRC has technical provisions allowing medical and industrial exceptions, the actual regulatory framework remains opaque and poorly codified. Tanzania maintains a strict prohibitionist stance domestically, though legal teams are monitoring regional trade pressures that may force a shift toward industrial hemp concessions heading into 2027.
For legal professionals structured across the continent, the core billing advisory centers on regulatory convergence and supply chain verification. Corporate lawyers must explicitly warn clients about the pervasive “corporate bias” in these emerging laws, which frequently impose steep permit fees (reaching up to $50,000 in certain regions) that marginalize smallholder farmers.
Structuring legally sound out-grower programs, ensuring compliance with international trade laws (INCB), and strictly parsing local definitions of THC content vs. CBD scheduling are the primary mechanisms to mitigate risk and unlock the multi-billion dollar potential of Africa’s green gold rush.
Strategic Next Steps for Practitioners
Cross-Border Integration: When structuring investments spanning multiple jurisdictions (e.g., a South African distributor sourcing from a Moroccan processor), utilize standardized international compliance templates.
Local Advisory Partnerships: Given the highly localized nature of law enforcement directives—such as South Africa’s internal police circulars regarding private transport—always retain on-the-ground criminal and agricultural co-counsel.
The Asia Pacific Region
The regulated cannabis and hemp markets in the Asia-Pacific (APAC) region are undergoing a profound changes as the market moves into 2027.
For lawyers and law firms, the era of speculative investment has transitioned into a highly litigious phase dominated by enforcement, technical administrative law, and multi-jurisdictional compliance.
The Australasian Prescription Challenge
Australia remains the commercial anchor of APAC, with its legal market expected to exceed USD 1 billion in 2026. However, the Therapeutic Goods Administration (TGA) has shifted from market facilitation to increased enforcement. In late 2025 and into 2026, patient supply volume fell by nearly 30% due to a regulatory crackdown on high-volume telehealth clinics and unapproved “closed-loop” prescribing under the Special Access Scheme (SAS-B).
Law firms are heavily engaged in defending corporate medical groups against TGA enforcement actions and advising on complex pricing-pressure disputes as median wholesale flower prices crash below AUD 10 per gram. Simultaneously, state-level litigation is rising, exemplified by New South Wales passing historic reforms to protect unimpaired medicinal cannabis patients from automatic drug-driving penalties, contrasting sharply with Queensland’s continued zero-tolerance stance.
In New Zealand, corporate legal practices are advising domestic licensed cultivators on survival tactics. With the country’s strict Medicinal Cannabis Scheme maintaining exceedingly high quality thresholds, firms are primarily handling cross-border export agreements and capital restructuring as local producers look to offload supply to Europe and Australia.
The Southeast Asian Pivot
Thailand serves as we will all now be aware, a cautionary tale of regulatory volatility. Following its un-codified decriminalization in 2022, the Ministry of Public Health has tightened controls under two Ministerial Regulations. Purely recreational “weed cafés” have been effectively squeezed out of operating with the majority of licenses now put to bed.
New rules mandate that cannabis flower licenses are strictly confined to medical facilities, pharmacies, or licensed traditional medicine practitioners.
Moving into 2027, the highly contested Cannabis and Hemp Act is pending parliamentary deliberation. Legal counsel in Bangkok are currently advising foreign investors on desperate compliance overhauls—specifically, converting standard dispensaries into licensed medical clinics or facing permanent closure.
Conversely, Malaysia represents a highly structured, risk-averse environment. Regulatory agencies are evaluating a strictly controlled, pharmaceutical-grade CBD framework. Lawyers in Kuala Lumpur are positioning themselves not for retail markets, but for clinical trial compliance, patent registrations, and government-backed research partnerships under the Dangerous Drugs Act.
The South Asian Legislative Awakening
In South Asia, the regulatory focus shifts entirely to industrial hemp and traditional medicines. India is experiencing a fragmented regulatory landscape. Individual states like Uttarakhand, Himachal Pradesh, and Madhya Pradesh have carved out localized commercial hemp cultivation frameworks. Lawyers in India are tracking the Food Safety and Standards Authority of India (FSSAI) guidelines regarding hemp seed products, alongside the Ministry of Ayush, which governs traditional Ayurvedic formulations utilizing cannabis extracts.
In Nepal, legislative momentum is building. Following a series of policy proposals aimed at exploiting the country’s natural cultivation advantages, lawyers are drafting the country’s first formal regulatory blueprints for medical export and industrial hemp.
Conversely, Pakistan is taking a centralized approach. Following the establishment of the Pakistan Cannabis Control Authority (PCCA), legal work in 2026 is concentrated on securing government-monopolized licenses for industrial hemp cultivation and processing, intended solely for the textile and medical export sectors.
Strategic Outlook for 2027
The 2027 market demands local expertise in administrative appeals against health regulators, complex IP and patent protection for proprietary extraction technologies, and cross-border trade law within a fragmented, highly sensitive regulatory environment.
Global Market Landscape: 2026–2027 Macro Trends
The global regulated cannabis and industrial hemp sectors are undergoing a historic, structural transformation, it may be slow but it is happening.
For years, the industry was defined by a fragmented, state-by-state patchwork of rules in the United States and a slow, speculative roll-out of legal frameworks internationally. In 2026, and moving into 2027, the market is shifting from an era of gray-market loopholes and localized compliance toward an institutionalized, corporate, and federally aligned global marketplace.
Driven by regulatory events, most notably the ongoing U.S. Drug Enforcement Administration (DEA) process to reclassify cannabis to Schedule III and the legislative closing of the “intoxicating hemp” loophole, the global market is projected to reach between $45 billion and $79 billion in 2026 and forecasts say it is on track to eclipse $100 billion by 2030. This transition from an illicit-adjacent frontier to a highly regulated consumer packaged goods (CPG) and life sciences category creates unprecedented, high-stakes demand for specialized corporate, regulatory, and litigation counsel.
The United States: Rescheduling and the Consolidation of Hemp
The single largest catalyst in the global market is the institutionalization of federal rescheduling in the U.S.. Moving cannabis from Schedule I to Schedule III under the Controlled Substances Act does not instantly legalize the industry nationwide, but it fundamentally re-rates the market’s capital structure. The immediate financial consequence is the elimination of Internal Revenue Code Section 280E, which historically barred cannabis businesses from deducting standard corporate business expenses. This change is projected to unlock billions in operational cash flow for Multi-State Operators (MSOs) like Curaleaf and Green Thumb Industries, which can now reinvest in cross-border infrastructure, brand acquisitions, and clinical research.
Concurrently, the booming market for unregulated, hemp-derived intoxicating cannabinoids (such as Delta-8 THC and THCA flower)—which exploded via ambiguities in the 2018 Farm Bill—is facing a coordinated legislative and executive shutdown. Sweeping federal actions through mid-to-late 2026 have systematically narrowed the definition of legal industrial hemp. By enforcing strict total-THC caps and reclassifying synthetic cannabinoids (like HHC) back into Schedule I, federal authorities are aggressively funneling all psychoactive cannabinoid commerce into a single, standardized regulatory framework.
Europe: Moving Toward Localized Commercialization and Pharmaceutical Standards
Europe represents the fastest-growing market by percentage, expected to expand rapidly toward a value of €2.5 billion by 2027. Rather than adopting a uniform, EU-wide market, the continent operates as a localized patchwork of more than 30 distinct legal regimes.
Germany remains the economic engine of the region. Following its sweeping 2024 decriminalization and the expansion of medical cannabis prescription capabilities, medical imports have surged past 200 tonnes annually. Moving into 2027, Germany is advancing its “Pillar 2” commercial pilot programs for adult-use retail networks. [1, 2]
The United Kingdom has institutionalized its Cannabis-Based Medicinal Products (CBMP) infrastructure, with the patient base expected to double by 2028.
Central & Eastern Europe are pivoting quickly, with the Czech Republic implementing its formal licensing framework in early 2026 and Poland doubling its year-over-year medical sales volumes.
The primary operational standard across Europe continues to be absolute adherence to EU Good Manufacturing Practices (EU-GMP) and Novel Foods compliance for non-psychoactive wellness products, enforcing a highly clinical, pharmaceutical approach to the plant.
Asia-Pacific and Latin America: Cultivation Hubs and Restricted Channels
Latin American jurisdictions (led by Colombia and Uruguay) are cementing their roles as low-cost agricultural and raw material export hubs, funneling compliant medical oils into high-value European and North American processing facilities.
In the Asia-Pacific region, which boasts a strong projected compound growth rate through 2031, strict medical barriers remain the norm. Australia dominates the regional landscape with a sophisticated, some would say over-regulated prescription and clinical trial ecosystem.
Meanwhile, Thailand serves as a cautionary tale of regulatory volatility; after full-scale decriminalization in 2022 led to an uninhibited retail market, the government in 2026 has aggressively clawed back open policies, subjecting thousands of dispensaries to strict medical certification and clinic-only distribution rules.
On The Horizon: Legal & Law Firm Opportunities
The transition of the cannabis and hemp sectors into mature, institutional markets means that generalist boutique cannabis firms are giving way to elite, multi-disciplinary practices within mid-market and Am Law 200 firms. For attorneys, 2026 and 2027 present specialized, highly lucrative focus areas.
| Practice Area | Primary Catalyst (2026–2027) | Nature of Legal Work & Billable Hours |
| Administrative & Regulatory Compliance | DEA Schedule III transition; Farm Bill hemp redefinitions; EU-GMP cross-border mandates. | Drafting multi-jurisdictional compliance protocols; defending against DEA, FDA, and state attorney general enforcement actions; structuring supply chains to pass international GACP/GMP audits. |
| Taxation & Controversy | Sunset of IRS Section 280E; retroactive tax credit disputes. | Navigating the corporate tax restructuring of major MSOs; litigating retroactive refund claims against the IRS; handling audits as corporate entities transition to normalized standard deductions. |
| Mergers & Acquisitions (M&A) | Market capitalization re-rating; distressed assets; CPG/Pharma entry. | Advising mainstream alcohol, tobacco, and pharmaceutical conglomerates looking to acquire distressed or undervalued cannabis brands; handling cross-border asset transfers and cross-continental joint ventures. |
| Intellectual Property (IP) | Rise of precision dosing, minor cannabinoids (CBN/CBG), and proprietary genetics. | Filing utility patents for nano-emulsification technologies and metered-dose inhalers; defending global trademark rights against cross-border counterfeiting; navigating international plant variety protections. |
| Banking, Finance & Securities | Continued federal financial exclusion; expansion of private credit. | Structuring complex private equity placements and secured credit facilities; advising financial institutions on FinCEN anti-money laundering (AML) and Suspicious Activity Report (SAR) compliance under the legacy 2014 guidelines. |
Strategic Imperatives for Law Firms Moving into 2027
To capture market share in this, now, maturing space, forward-looking law firms will be shifting away from localized, application-focused licensing work and positioning themselves as strategic, long-term enterprise partners.
Build Cross-Border Transatlantic Practices: With Germany, the UK, Australia, and the U.S. operating on distinct timelines but increasingly trading with one another, MSOs require law firms that can seamlessly clear regulatory hurdles across multiple continents simultaneously. Firms will be thinking about establishing robust international trade and life sciences capabilities to guide clients through the complex web of cross-border supply agreements and international narcotic treaties.
Brace for High-Stakes Litigation: The tightening of hemp laws and the restructuring of state-legal cannabis rules are creating friction. Law firms will find massive opportunities in administrative litigation, challenging state-level product bans, defending clients against consumer class-action suits over product labeling, and managing complex partnership disputes born out of the previous market downturn.
Target Mainstream CPG and Institutional Capital Clients: As the legal risk profile drops due to the Schedule III transition, traditional institutional funds, commercial banks, and massive consumer product brands that previously stood on the sidelines are actively preparing for market entry. Law firms that already possess strong, existing relationships in traditional sectors are uniquely positioned to serve as the bridge, advising these risk-averse institutions on how to safely deploy capital and execute strategic acquisitions within the newly synchronized global cannabinoid market.
Lawyer Roundup
I would also like to repeat once again, this year, that we are seeing more women not only working in cannabis practices but starting their own, I’d like to highlight Rudick law firm based out of New York, here.
We aren’t, by any means, at 50/50 yet (the sooner we get there the better) but I hope that the make up of this year’s edition of the directory goes some way to illustrating these changes.
Names to mention would include amongst many others. In no particular order: Lauren Rudick, Heidi Urness (now solo), Shannett Thompson (UK), Samantha Myers (UK), Chelsie Spencer, Courtney Barnes, Courtney Moran, Janet Jackim, Sita Schubert(Germany) & Susan Burns amongst many others.
Again this past year has seen big developments in the divide between the “cannabis” industry and the “hemp industry for human consumption”and now a federal deadline to decide where the path will lead us all falls in December.
Whatever side of the various argument(s) you fall, depends, but we would highlight the one lawyer who really understand the distinctions, Rod Kight His tireless advocacy is really something of a wonder and especially as the tables have turned against hemp for human consumption.
And finally to our superstars. As I have already mentioned I don’t rank lawyers in the Top 200 but there are a few superstars out there I would very much like to mention.
Although I have already named Rod Kight I’m going to highlight his work for a second time. He’s decided not to ply his craft at a large law firm and there isn’t a lawyer, client or cannabis advocate out there who isn’t impressed by the work he is doing.
The same also applies to Lauren Rudick who runs her own tight knit firm with some excellent supporting lawyers. I’d like also to mention Mitchel Chargo at Hinshaw who played a large part in formulating a world first in Michigan’s cannabis pact with local indigenous communities that could well be the basis for a nationwide template. Also, be warned Bob Hoban’s quiet extended sabbatical looks as though it is over and I’m guessing you’ll be seeing him more on the world stage.
Now re-scheduling is the thing in the US we’ve seen the likes of Eric Berlin of Dentons(US) and Brian Vicente a lot more active in providing advice (I’d call it lobbying) in DC and state houses around the US.
Fewer and fewer lawyers seem to see the value in sharing knowledge these days through applying time to the art of writing about the topics of the day and so special shout outs should go to Whitt Steineker (Bradley), Rod Kight ( yes him again!) and Jason Adelstone of Harris Sliwoski which in this day and age is apparently called, thought leadership, I just call it writing and let’s have more of it please.
The final word goes to those lawyers who think of cannabis as more than just a business or industry sector. I believe that in this field the South Africans lead the world and Ricky Stone and Paul Michael Keichel of Cullinans are exemplars in this regard . Talking about community, the environment and ethics in cannabis appears to be somewhat out of fashion these days. I suggest many lawyers should beat a path to their door and learn how cannabis lawyering is really done and Ricky I should hasten to add is really an environmental law bod.
Congratulations to all the practitioners in the 7th Edition (2026-2027) of The Global Top 200 Cannabis Lawyers and thank you to all of you, especially those we haven’t been able to mention by name.
Keep doing what you do.
Sean Hocking
Editor – Global Top 200 Cannabis Lawyers